Deutsche Bank raised the firm’s price target on Novartis (NVS) to CHF 125 from CHF 120 and keeps a Buy rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Novartis receives FDA Breakthrough Therapy designation for ianalumab
- Trump Trade: White House releases details on ‘Great Healthcare Plan’
- Drugmakers concerned about legal risk with FDA review program, Reuters reports
- Novartis: Buy Rating Backed by Strong Rx Momentum, De-Risked Late-Stage Pipeline and Attractive Valuation
- White House releases details on Trump ‘Great Healthcare Plan’